UMSOM wins $3.5 million BARDA contract to develop animals models for radiation research

NewsGuard 100/100 Score

University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that UMSOM faculty scientists have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for the federal agency's Radiation Nuclear Animal Model Development program. The $3.5 million award that Erika Davies, PhD, Assistant Professor of Radiation Oncology, received to develop Acute Radiation Syndrome Animal Models, has a $16 million potential total. The Division of Translational Radiation Sciences (DTRS), within the Department of Radiation Oncology, will support this project.

Dr. Davies and her colleagues are working with BARDA to advance the development of radiologic and nuclear countermeasures. This is part of a broader effort to enhance national preparedness for radiation accidents and emergencies. "We're trying to develop and test new treatments that can be used in a terror attack scenario that involves high radiation exposure," said Dr. Davies. "We are developing robust animal models that will translate well to humans."

BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS).

Currently, relatively few medical treatments are available to counter radiological and nuclear threats as FDA approval requires extensive preclinical efficacy and safety data to support drug approval. Many more such agents are needed, based on the range of options that could be employed by terrorists, the need for urgent intervention following radiation exposure, and the medical complexities of acute and chronic radiation injury.

The DTRS is uniquely positioned to provide leading expertise in medical countermeasures research. We are bridging first-in-class radiation science with contract research to increase the likelihood of survival in a radiation or nuclear incident, while simultaneously identifying a potential new class of therapeutics for cancer patients undergoing radiation therapy."

William Regine, MD, the Isadore & Fannie Schneider Foxman Chair of Radiation Oncology at UMSOM

Almost a decade ago research by DTRS faculty and staff led to the approval of the first drug to treat the deleterious effects of radiation exposure following a nuclear incident based on efficacy data generated in animal models. Animal models are especially important in preparing for radiation emergencies, because the efficacy of most experimental treatments cannot be tested in humans.

"DTRS is able to develop different experimental models through its world class 'Good Laboratory Practice'-compliant testing facility, which houses one of the nation's most well-equipped suites of technologies supporting radiation research," said Dr. Gladwin who is the John Z. and Akiko K. Bowers Distinguished Professor and Dean of UMSOM, and Vice President for Medical Affairs at University of Maryland, Baltimore. "Our faculty's collaborative expertise from across the broadest spectrum of countermeasure investigations, allow the rapid configuration and implementation of solutions-oriented approaches to even the most difficult challenges."

The work with BARDA will include multiple individual projects that draw on changing configurations of DTRS experts, instrumentation, and specialized resources, as well as on collaborations with other UMSOM and University of Maryland, Baltimore investigators.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI and predictive medicine: Recent advances